Gene-editing companies Synthego and HuidaGene Therapeutics have entered a collaboration to license HuidaGene's high-fidelity Cas12 CRISPR nuclease (hfCas12Max). The terms and financial details of the agreement have not been disclosed.
As per the agreement, HuidaGene will grant Synthego the rights to manufacture and commercialize the hfCas12Max nuclease and sublicense it for therapeutic use.
The collaboration aims to streamline the development of CRISPR-based therapeutic applications, providing developers access to efficient genome-editing tools.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.